Randomised, Split-Face Study of Dermocosmetic Cream for Rosacea
Published in Skin Research and Technology, June 2024
Objective: To assess the benefit of a dermocosmetic cream (DC cream) containing Sphingobioma xenophaga extract and soothing agent in adult females with rosacea-associated erythema and sensitive skin.
Methods: The study involved a 28-day phase where DC was applied twice daily on one half of the face and compared to usual-skincare (USC), followed by a 56-day phase of applying DC on the full face. Clinical, instrumental, and skin sensitivity assessments were performed at all visits.
Results: At day 28, DC showed significant benefits over USC for erythema, tightness, burning, stinging, erythema measured by chromameter, corneometry, transepidermal water loss, skin sensitivity, and mean demodex density reduction. At day 84, DC significantly improved clinical signs and symptoms on both sides of the face, with notable improvements in stigmatization questionnaire scores, ROSAQoL, and DLQI scores.
Conclusion: DC significantly improved erythema, skin sensitivity, demodex count, quality of life, and feeling of stigmatization in subjects with rosacea and was well tolerated.
Value of Clinical Trials in Healthcare
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
Practical Solutions for Healthcare Operations
Streamlining operations is crucial in today’s healthcare environment. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes while reducing paper routines.
Learn more about how we can help at aidevmd.com.
